Endoscopy 2014; 46(07): 619-624
DOI: 10.1055/s-0034-1365505
Case report/series
© Georg Thieme Verlag KG Stuttgart · New York

Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland

Michael C. Sulz
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Remus Frei
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Christa Meyenberger
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Peter Bauerfeind
2   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Switzerland
,
Gian-Marco Semadeni
1   Department of Gastroenterology and Hepatology, Kantonspital St. Gallen, Switzerland
,
Christoph Gubler
2   Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital of Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

submitted 31 December 2013

accepted after revision 20 January 2014

Publication Date:
25 April 2014 (online)

Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a hemostatic agent recently introduced for the management of upper gastrointestinal bleeding (GIB). To date, there is little experience with this fairly new hemostatic tool. The aim of this case series was to reflect the use and effectiveness of Hemospray as a treatment option in GIB in everyday clinical practice at two tertiary referral centers. Consecutive patients (n = 16) with active GIB of various origins were treated with Hemospray. The rate of successful initial hemostasis was 93.75 % (15 /16; salvage therapy 92.85 % [13/14]; monotherapy 100 % [2 /2]). The rebleeding rate within 7 days was 12.5 % (2/16). One patient, in whom interventional radiology also failed, had to undergo surgery as salvage therapy. The effectiveness of Hemospray in the management of GIB in various clinical situations is promising. Future multicenter randomized prospective trials for clearly defined bleeding situations are needed for greater generalizability of case series findings.

 
  • References

  • 1 Sung JJ, Luo D, Wu JC et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
  • 2 Chen YI, Barkun AN, Soulellis C et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-1281
  • 3 Soulellis CA, Carpenter S, Chen YI et al. Lower gastrointestinal hemorrhage controlled with endoscopically applied TC-325: (with videos). Gastrointest Endosc 2013; 77: 504-507
  • 4 Holster IL, Kuipers EJ, Tjwa ET. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013; 45: 63-66
  • 5 Smith LA, Stanley AJ, Bergman JJ et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: Results of the survey to evaluate the application of Hemospray in the luminal tract. J Clin Gastroenterol 2013; PMID: 24326829. Epub 2013 Dec 10
  • 6 Khamaysi I, Gralnek IM. Acute upper gastrointestinal bleeding (UGIB) – initial evaluation and management. Best Pract Res Clin Gastroenterol 2013; 27: 633-638
  • 7 Holster IL, Brullet E, Kuipers EJ et al. Hemospray treatment is effective for lower gastrointestinal bleeding. Endoscopy 2014; 46: 75-78
  • 8 Holster IL, Poley JW, Kuipers EJ et al. Controlling gastric variceal bleeding with endoscopically applied hemostatic powder (Hemospray™). J Hepatol 2012; 57: 1397-1398
  • 9 Stanley AJ, Smith LA, Morris AJ. Use of hemostatic powder (Hemospray) in the management of refractory gastric variceal hemorrhage. Endoscopy 2013; 45 Epub 2013 Mar 22 E86-E87 DOI: 10.1055/s-0032-1326258.
  • 10 Moosavi S, Chen YI, Barkun AN. TC-325 application leading to transient obstruction of a post-sphincterotomy biliary orifice. Endoscopy 2013; 45: E130 Epub 2013 May 28 DOI: 10.1055/s-0032-1326370.